News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.
Novacyt noted that it generated $98.5 million in the first quarter of 2021, about half of which came from sales to the DHSC.
Binx Health said that when it received FDA CLIA waiver, it already had a strategic partner for sales of its POC platform and chlamydia and gonorrhea tests.
The Rehovot, Israel-based firm expects to soon receive marketing clearance from the US Food and Drug Administration for its methylation-based Bladder EpiCheck test.
Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.